
codex
**Verdict: FAIL. G1 is not ready to pass, including with narrowing.** The package establishes usable environmental contrasts, but it has not established an identifiable transfer endpoint, independent validation cohort, or adequate preprocessing provenance. These are substantive gaps.

I read the requested records and handoff §§5–7. All 12 manifested local files match their recorded sizes and SHA-256 hashes. Broad CSV checks reproduce the matrix dimensions, pairing counts, and reported direction correlations. I made no edits and inspected no additional Sanger outcome values. Current Figshare manifests and the S3 Zenodo archive were inaccessible through the available routes, so their contents remain independently unverified.

1. **[CRITICAL] The named question is not yet an operational, answerable estimand.**  
   [g1_question_candidate.md:4](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_candidate.md:4) leaves “transfer degradation of dependency behavior” undefined. A shift in dependency levels, loss of expression–dependency association, and loss of predictive rank correlation are different outcomes. The required genome-wide development matrices are still unavailable.

   **Fix:** Name one numerical transfer endpoint, its reference population, comparator, eligible targets, and required inputs. Demonstrate that those inputs can actually be joined. Published NextGen-versus-traditional test tables cannot replace individual-level prediction data while retaining the same question; that fallback is a different descriptive study.

2. **[CRITICAL] Outcome-guided panel selection creates a circularity risk that acknowledgment does not resolve.**  
   [provenance_v1.md:7](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:7) acknowledges selection using Broad 2D–3D dependency differences. The proposed transfer endpoint may reuse those differences or their constituent observations. Conditioning on lineage and baseline strength does not automatically remove this selection effect.

   **Fix:** Trace the exact selection inputs and their overlap with every proposed evaluation cohort. Treat Broad reuse as development evidence. External confirmation can support a claim conditional on the fixed selected panel only after excluding donor overlap and outcome-dependent shared processing. Do not generalize to unselected genes.

3. **[CRITICAL] Preprocessing independence remains unaudited.**  
   [provenance_v1.md:27](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:27) records a flag rather than a resolved dependency graph. Choosing a study-specific release does not establish independence. Sanger’s public pipeline also contains transformations fitted using outcomes across samples, including spline correction and ComBat. This establishes an audit requirement, not proof that A and C are contaminated. [Sanger processing code](https://raw.githubusercontent.com/Garnett-Lab/SangerOrganoidBiobank/main/scripts/CRISPR_pipeline.R).

   **Fix:** Record which observations fitted each correction, library parameter, normalization, and selection rule. Establish whether any evaluation outcomes influenced development artifacts. Where they did, reconstruct development-only processing or obtain independent evidence. Reserve “transductive covariate preprocessing” for covariate-only operations.

4. **[HIGH] Seven models is the overall count, not the independent count for either contrast.**  
   The pair keys in [identifiability_audit.json:14](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:14) imply:

   | Contrast | Matched contrasts | Distinct models | Verified independent donors |
   |---|---:|---:|---|
   | Medium | 5 | **4** | Unresolved |
   | Format | 7 | **6** | Unresolved |

   ACH-003040 contributes twice to each contrast type and is the only complete four-condition model. Treating all contrasts equally also gives it extra weight.

   **Fix:** Report contrast-specific model and donor counts; define weights and retain shared-model covariance. Genes are correlated targets, not additional patients. A joint bootstrap preserves dependence only if its grouping and estimand are correct; it does not create additional biological support.

5. **[HIGH] “Heterogeneity dominates” is unsupported by the reported sign-flip statistic.**  
   [identifiability_audit.json:53](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:53) turns any positive and negative observed changes into evidence of biological heterogeneity. My Broad-only check found:

   | Gene group | Medium: both signs | Format: both signs |
   |---|---:|---:|
   | 250 test genes | 90.8% | 98.4% |
   | 750 controls | **92.1%** | **98.1%** |

   For illustration, independent symmetric zero-effect noise produces both signs with probability \(1-2^{1-k}\): 93.75% for five observations and 98.44% for seven. That is not a calibrated null for this dependent design, but it demonstrates why sign flips alone prove little.

   **Fix:** Retract “heterogeneity dominates” and “average effects are near-uninterpretable.” Assess magnitudes against technical variation and controls. Report meaningful opposing effects where supported. Do not expand into poorly supported context strata because tiny estimates cross zero.

6. **[HIGH] The required observation-level provenance and attrition registry is missing.**  
   [provenance_v1.md:26](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:26) leaves donor crosswalks open. The record does not supply the handoff’s complete model/donor/origin/laboratory/library/condition/replicate table or attempted-condition attrition.

   The Broad README documents 34 sequencing attempts and a removed replicate; the analysis matrix contains collapsed screen estimates. Zero matrix missingness does not establish complete experimental coverage.

   **Fix:** Build the observation table and distinguish unattempted conditions, growth failures, QC exclusions, and unavailable metadata. Recover replicate identities and document which uncertainty components are estimable. Resolve ACH-003052 or exclude it from claims requiring the missing annotation.

7. **[HIGH] Treatment scope and confounding need explicit limits.**  
   The interventions change bundles: plastic versus Matrigel dome changes matrix exposure as well as geometry; OPAC versus RPMI/FBS changes medium composition beyond serum. Sparse condition coverage also limits separation of model, lineage, origin, and interaction effects.

   **Fix:** Name the actual treatment bundles. Restrict intervention interpretations to observed within-model comparisons. Do not claim isolated geometry, serum, genotype modification, or causal explanation of external transfer failure. Across-cohort association remains compatible with laboratory, library, state, and population differences.

8. **[HIGH] The Sanger validation outcome is not established by the downloaded candidate file.**  
   [provenance_v1.md:33](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:33) reports 930 ACH columns, whereas the covariates describe HCM-SANG organoids. A crosswalk cannot substitute for establishing whether the required organoid measurements are present. The continuous LFC matrix is named but absent from the supplied manifest.

   **Fix:** Establish object identities, cohort membership, screen/library identifiers, target coverage, and the authoritative continuous-outcome route through schema and documentation. Resolve duplicate-library selection. Binary BAGEL calls require a different endpoint and cannot silently replace continuous rank-transfer evidence. Ranking avoids absolute-scale equivalence; it does not eliminate assay effects.

9. **[HIGH] The Sanger glimpse is disclosed, but its disposition is insufficient.**  
   [exposure_log.jsonl:2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/exposure_log.jsonl:2) labels 18 cells “de minimis” without identifying their targets, samples, or relationship to eligible C observations. The 930-column schema makes even the description “Sanger glimpse” uncertain.

   **Fix:** Recover the displayed identifiers from retained transcripts without reopening values; map them to candidate cohorts and document downstream decisions. At minimum, affected claims lose an entirely outcome-unseen designation. Conservatively exclude exposed donors or targets where appropriate, or use fresh evidence if influence cannot be bounded. **The entire Sanger resource need not automatically be discarded, but current handling does not justify an intact blinding claim.**

10. **[HIGH] Layer B cannot become untouched merely through a later split.**  
    [partitions_provisional.json:8](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/partitions_provisional.json:8) proposes carving B from Layer A after whole-panel outcome inspection and aggregate analyses.

    **Fix:** Reserve genuinely uninspected evidence or explicitly classify later evaluation on these observations as reused-data engineering evaluation. Gene or pathway partitions within the same measured models do not establish independent biological tasks. Final manifests must record exposure history alongside membership.

11. **[HIGH] A plausible novelty gap remains, but novelty has not been established at the proposed resolution.**  
    [novelty_audit_v1.md:13](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:13) overstates “nobody has tested.” S1 reports individual-gene environmental findings and paired results, not only class summaries. S2 includes context-specific functional findings; S3 already examines transfer attenuation and distinguishes target-wise prediction from within-organoid ranking. [S1](https://www.nature.com/articles/s41586-026-10843-7), [S2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13581617/), [S3](https://www.mdpi.com/2079-7737/15/19/1782).

    **Fix:** Complete the listed supplement/code reads and preserve exact searches and exclusions locally. Audit each precise claim against prior figures, targets, and endpoints. The potentially open contribution is a bounded relationship between measured environmental contrasts and independently evaluated transfer degradation—not heterogeneity alone or familiar lipid/adhesion effects. Failure of S3 to answer that question does not establish that this design can answer it.

12. **[HIGH] Falsification and precision rules remain inadequate.**  
    [g1_question_candidate.md:7](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_candidate.md:7) offers several movable alternatives. “No association” is not a falsifier when intervals are wide. A positive association can coexist with an effect below δ. Choosing δ from attainable precision risks redefining scientific importance to fit available data.

    **Fix:** Define one primary parameter, a scientifically justified practical threshold, disjoint decision rules, and an inconclusive region. Perform a precision-feasibility assessment using four/six environmental model clusters and the actual eligible transfer donors. Seven models do not automatically prohibit every panel-wide association; they do not justify an adaptive gene-class × genotype × context search either.

13. **[MEDIUM] Manifest completeness and reproducibility fall short of “verified provenance.”**  
    [source_manifest_sanger_figshare.json:1](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/source_manifest_sanger_figshare.json:1) omits the downloaded Jaccard and VAF files. Neither manifest pins an article version or preserves the authoritative manifest response. Local hash agreement establishes file integrity, not source accuracy. Also, [audit_minipool.py:59](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/src/audit_minipool.py:59) does not regenerate the JSON’s direction-check results.

    **Fix:** Manifest every imported source, pin versions/commits, retain source responses and license evidence, and make the audit regenerate its reported outputs. Document the primary-source QC discrepancy: Methods state 500,000 reads, while Extended Data Fig. 9 states five million.

The required narrowing is substantial: **one fixed environmental contrast, one fixed eligible target family, and one panel-wide associational transfer parameter**, conditional on the selected genes and measured models. For example, medium contrasts in dome have four model supports. Remove adaptive context-stratification and causal-attribution promises unless additional evidence supplies identification. Published group-comparison tables could support a separate descriptive concordance question, which needs its own novelty justification.

Before G1 can pass, complete the crosswalk/count/attrition table; resolve preprocessing independence and the actual transfer-data route; correct the heterogeneity interpretation; adjudicate exposure and B reuse; and document an exact, plausibly novel, feasible question. Phase 2 can then finalize the endpoint, meaningful margins, baselines, uncertainty procedure, multiplicity, eligibility, partitions, invalid-result rules, and hashes required for Lock 1. Those later implementation requirements should not be confused with the unresolved G1 evidence requirements.

SCORE: 56
tokens used
138,566
**Verdict: FAIL. G1 is not ready to pass, including with narrowing.** The package establishes usable environmental contrasts, but it has not established an identifiable transfer endpoint, independent validation cohort, or adequate preprocessing provenance. These are substantive gaps.

I read the requested records and handoff §§5–7. All 12 manifested local files match their recorded sizes and SHA-256 hashes. Broad CSV checks reproduce the matrix dimensions, pairing counts, and reported direction correlations. I made no edits and inspected no additional Sanger outcome values. Current Figshare manifests and the S3 Zenodo archive were inaccessible through the available routes, so their contents remain independently unverified.

1. **[CRITICAL] The named question is not yet an operational, answerable estimand.**  
   [g1_question_candidate.md:4](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_candidate.md:4) leaves “transfer degradation of dependency behavior” undefined. A shift in dependency levels, loss of expression–dependency association, and loss of predictive rank correlation are different outcomes. The required genome-wide development matrices are still unavailable.

   **Fix:** Name one numerical transfer endpoint, its reference population, comparator, eligible targets, and required inputs. Demonstrate that those inputs can actually be joined. Published NextGen-versus-traditional test tables cannot replace individual-level prediction data while retaining the same question; that fallback is a different descriptive study.

2. **[CRITICAL] Outcome-guided panel selection creates a circularity risk that acknowledgment does not resolve.**  
   [provenance_v1.md:7](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:7) acknowledges selection using Broad 2D–3D dependency differences. The proposed transfer endpoint may reuse those differences or their constituent observations. Conditioning on lineage and baseline strength does not automatically remove this selection effect.

   **Fix:** Trace the exact selection inputs and their overlap with every proposed evaluation cohort. Treat Broad reuse as development evidence. External confirmation can support a claim conditional on the fixed selected panel only after excluding donor overlap and outcome-dependent shared processing. Do not generalize to unselected genes.

3. **[CRITICAL] Preprocessing independence remains unaudited.**  
   [provenance_v1.md:27](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:27) records a flag rather than a resolved dependency graph. Choosing a study-specific release does not establish independence. Sanger’s public pipeline also contains transformations fitted using outcomes across samples, including spline correction and ComBat. This establishes an audit requirement, not proof that A and C are contaminated. [Sanger processing code](https://raw.githubusercontent.com/Garnett-Lab/SangerOrganoidBiobank/main/scripts/CRISPR_pipeline.R).

   **Fix:** Record which observations fitted each correction, library parameter, normalization, and selection rule. Establish whether any evaluation outcomes influenced development artifacts. Where they did, reconstruct development-only processing or obtain independent evidence. Reserve “transductive covariate preprocessing” for covariate-only operations.

4. **[HIGH] Seven models is the overall count, not the independent count for either contrast.**  
   The pair keys in [identifiability_audit.json:14](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:14) imply:

   | Contrast | Matched contrasts | Distinct models | Verified independent donors |
   |---|---:|---:|---|
   | Medium | 5 | **4** | Unresolved |
   | Format | 7 | **6** | Unresolved |

   ACH-003040 contributes twice to each contrast type and is the only complete four-condition model. Treating all contrasts equally also gives it extra weight.

   **Fix:** Report contrast-specific model and donor counts; define weights and retain shared-model covariance. Genes are correlated targets, not additional patients. A joint bootstrap preserves dependence only if its grouping and estimand are correct; it does not create additional biological support.

5. **[HIGH] “Heterogeneity dominates” is unsupported by the reported sign-flip statistic.**  
   [identifiability_audit.json:53](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:53) turns any positive and negative observed changes into evidence of biological heterogeneity. My Broad-only check found:

   | Gene group | Medium: both signs | Format: both signs |
   |---|---:|---:|
   | 250 test genes | 90.8% | 98.4% |
   | 750 controls | **92.1%** | **98.1%** |

   For illustration, independent symmetric zero-effect noise produces both signs with probability \(1-2^{1-k}\): 93.75% for five observations and 98.44% for seven. That is not a calibrated null for this dependent design, but it demonstrates why sign flips alone prove little.

   **Fix:** Retract “heterogeneity dominates” and “average effects are near-uninterpretable.” Assess magnitudes against technical variation and controls. Report meaningful opposing effects where supported. Do not expand into poorly supported context strata because tiny estimates cross zero.

6. **[HIGH] The required observation-level provenance and attrition registry is missing.**  
   [provenance_v1.md:26](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:26) leaves donor crosswalks open. The record does not supply the handoff’s complete model/donor/origin/laboratory/library/condition/replicate table or attempted-condition attrition.

   The Broad README documents 34 sequencing attempts and a removed replicate; the analysis matrix contains collapsed screen estimates. Zero matrix missingness does not establish complete experimental coverage.

   **Fix:** Build the observation table and distinguish unattempted conditions, growth failures, QC exclusions, and unavailable metadata. Recover replicate identities and document which uncertainty components are estimable. Resolve ACH-003052 or exclude it from claims requiring the missing annotation.

7. **[HIGH] Treatment scope and confounding need explicit limits.**  
   The interventions change bundles: plastic versus Matrigel dome changes matrix exposure as well as geometry; OPAC versus RPMI/FBS changes medium composition beyond serum. Sparse condition coverage also limits separation of model, lineage, origin, and interaction effects.

   **Fix:** Name the actual treatment bundles. Restrict intervention interpretations to observed within-model comparisons. Do not claim isolated geometry, serum, genotype modification, or causal explanation of external transfer failure. Across-cohort association remains compatible with laboratory, library, state, and population differences.

8. **[HIGH] The Sanger validation outcome is not established by the downloaded candidate file.**  
   [provenance_v1.md:33](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v1.md:33) reports 930 ACH columns, whereas the covariates describe HCM-SANG organoids. A crosswalk cannot substitute for establishing whether the required organoid measurements are present. The continuous LFC matrix is named but absent from the supplied manifest.

   **Fix:** Establish object identities, cohort membership, screen/library identifiers, target coverage, and the authoritative continuous-outcome route through schema and documentation. Resolve duplicate-library selection. Binary BAGEL calls require a different endpoint and cannot silently replace continuous rank-transfer evidence. Ranking avoids absolute-scale equivalence; it does not eliminate assay effects.

9. **[HIGH] The Sanger glimpse is disclosed, but its disposition is insufficient.**  
   [exposure_log.jsonl:2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/exposure_log.jsonl:2) labels 18 cells “de minimis” without identifying their targets, samples, or relationship to eligible C observations. The 930-column schema makes even the description “Sanger glimpse” uncertain.

   **Fix:** Recover the displayed identifiers from retained transcripts without reopening values; map them to candidate cohorts and document downstream decisions. At minimum, affected claims lose an entirely outcome-unseen designation. Conservatively exclude exposed donors or targets where appropriate, or use fresh evidence if influence cannot be bounded. **The entire Sanger resource need not automatically be discarded, but current handling does not justify an intact blinding claim.**

10. **[HIGH] Layer B cannot become untouched merely through a later split.**  
    [partitions_provisional.json:8](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/partitions_provisional.json:8) proposes carving B from Layer A after whole-panel outcome inspection and aggregate analyses.

    **Fix:** Reserve genuinely uninspected evidence or explicitly classify later evaluation on these observations as reused-data engineering evaluation. Gene or pathway partitions within the same measured models do not establish independent biological tasks. Final manifests must record exposure history alongside membership.

11. **[HIGH] A plausible novelty gap remains, but novelty has not been established at the proposed resolution.**  
    [novelty_audit_v1.md:13](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:13) overstates “nobody has tested.” S1 reports individual-gene environmental findings and paired results, not only class summaries. S2 includes context-specific functional findings; S3 already examines transfer attenuation and distinguishes target-wise prediction from within-organoid ranking. [S1](https://www.nature.com/articles/s41586-026-10843-7), [S2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13581617/), [S3](https://www.mdpi.com/2079-7737/15/19/1782).

    **Fix:** Complete the listed supplement/code reads and preserve exact searches and exclusions locally. Audit each precise claim against prior figures, targets, and endpoints. The potentially open contribution is a bounded relationship between measured environmental contrasts and independently evaluated transfer degradation—not heterogeneity alone or familiar lipid/adhesion effects. Failure of S3 to answer that question does not establish that this design can answer it.

12. **[HIGH] Falsification and precision rules remain inadequate.**  
    [g1_question_candidate.md:7](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_candidate.md:7) offers several movable alternatives. “No association” is not a falsifier when intervals are wide. A positive association can coexist with an effect below δ. Choosing δ from attainable precision risks redefining scientific importance to fit available data.

    **Fix:** Define one primary parameter, a scientifically justified practical threshold, disjoint decision rules, and an inconclusive region. Perform a precision-feasibility assessment using four/six environmental model clusters and the actual eligible transfer donors. Seven models do not automatically prohibit every panel-wide association; they do not justify an adaptive gene-class × genotype × context search either.

13. **[MEDIUM] Manifest completeness and reproducibility fall short of “verified provenance.”**  
    [source_manifest_sanger_figshare.json:1](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/source_manifest_sanger_figshare.json:1) omits the downloaded Jaccard and VAF files. Neither manifest pins an article version or preserves the authoritative manifest response. Local hash agreement establishes file integrity, not source accuracy. Also, [audit_minipool.py:59](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/src/audit_minipool.py:59) does not regenerate the JSON’s direction-check results.

    **Fix:** Manifest every imported source, pin versions/commits, retain source responses and license evidence, and make the audit regenerate its reported outputs. Document the primary-source QC discrepancy: Methods state 500,000 reads, while Extended Data Fig. 9 states five million.

The required narrowing is substantial: **one fixed environmental contrast, one fixed eligible target family, and one panel-wide associational transfer parameter**, conditional on the selected genes and measured models. For example, medium contrasts in dome have four model supports. Remove adaptive context-stratification and causal-attribution promises unless additional evidence supplies identification. Published group-comparison tables could support a separate descriptive concordance question, which needs its own novelty justification.

Before G1 can pass, complete the crosswalk/count/attrition table; resolve preprocessing independence and the actual transfer-data route; correct the heterogeneity interpretation; adjudicate exposure and B reuse; and document an exact, plausibly novel, feasible question. Phase 2 can then finalize the endpoint, meaningful margins, baselines, uncertainty procedure, multiplicity, eligibility, partitions, invalid-result rules, and hashes required for Lock 1. Those later implementation requirements should not be confused with the unresolved G1 evidence requirements.

SCORE: 56
